JBR Clinical Research
Salt Lake City, Utah, 84107, United States
NCT Number: NCT06774625
The goal of this clinical trial is to learn if LTG-001 works to treat pain after third molar removal surgery in adults. It will also learn about the safety of LTG-001. The main questions it aims to answer are:
Does drug LTG-001 treat the acute pain after surgical removal of impacted third molars (wisdom teeth) over 12 hours? How tolerable is LTG-001 after surgical removal of impacted third molars (wisdom teeth) over 12 hours?
Researchers in Part 1 will compare drug LTG-001 to a placebo (a look-alike substance that contains no drug) and in Part 2 to a placebo and a comparator to see if drug LTG-001 treats the post-surgical pain.
Participants will:
Take LTG-001 one time after the surgical removal of impacted third molars. Remain at the clinic for 12 hours after study dosing and return after a week for a safety check up.
Report the pain relief during the 12 hours after dosing to record changes in the post-operative pain
Looking for future studies?
Notify Me18 year–50 year
All sexes
Interventional
Phase 2
Salt Lake City, Utah, 84107, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
LTG-001 High Dose
Other names: LTG-001
LTG-001 Mid Dose
LTG-001 Low Dose
Placebo
Active comparator - Nav1.8 inhibitor
Time frame: 12 hours
Pain Intensity NRS Score change over the study.
Time frame: 12 hours
Time to Confirmed Perceptible Pain Relief, assessed via 2-stopwatch technique.
Time frame: 12 hours
Time to Meaningful Pain Relief, assessed via 2-stopwatch technique.
Time frame: 12 hours
Time to first use of rescue medication.
Time frame: 12 hours
Time-weighted summed pain relief as recorded on a sum of total pain relief (TOTPAR) over 0 to 12 hours (TOTPAR12) after the first dose of study drug.
Time frame: 12 hours
Time to ≥ 2-point reduction in Numerical Rating Scale from baseline compared to placebo.
Time frame: 12 hours
Subject's global evaluation based on a 5-point scale asking, "Overall, how effective do you think the study drug is as a treatment for pain?"
Time frame: 12 hours
Subjects requiring no rescue opioid over 12 hours.
Time frame: 12 hours
Total opioid rescue consumption over 12 hours.
Latigo Biotherapeutics
Industry
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of LTG 001 for Acute Pain After Surgical Removal of Impacted Third Molars
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06673979
Acute Pain, Acute Pain, Postoperative
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07336264
Acute Pain, Acute Pain, Postoperative
Washington D.C., District of Columbia, United States
View Trial DetailsNCT06659965
Acute Pain, Postoperative, Acute Post Operative Pain
Houston, Texas, United States
View Trial DetailsNCT06843343
Acute Pain, Postoperative, Neurologic Manifestations
Durham, North Carolina, United States
View Trial Details